‍

Cell therapies have transformative potential in cancers and rare diseases. To bring these benefits to patients we need innovations to address the cost, manufacturing, and scalability challenges.

RSVP to join us in Boston on Nov 12, 2025 for the panel "Cell Therapy Investments in the AI Age."

Hear from panelists including Nagisa Sakurai, PhD, investment lead at Astellas Pharma; Micha Breakstone, PhD, CEO of Somite AI; Sebastien Latapie, partner at Avant Bio. Maximilian von Poelnitz, Ajinomoto Group Ventures managing director will moderate the panel.

How can AI foundation models shorten the cell therapy developments from discovery to human trials?

What role can AI play in reducing cost per dose? Will it help make therapies accessible beyond rare diseases?

How will pharma and AI-native companies collaborate most effectively in the next five years?

RSVP required. Sign up in this link.

‍